1022 views3 min read

Silo Pharma Announces Participation on Webull Corporate Communications Service Platform

Silo PharmaJune 3, 2023

Silo Pharma, Inc.Webull’s investor community can now access the SILO profile for real-time data and investor communicationsENGLEWOOD CLIFFS, NJ, June 02, 2023 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today ann... Read More...

Calendar1126 views3 min read

Numinus to Participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023

Numinus WellnessJune 2, 2023

VANCOUVER, BC, June 2, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will participate in a Water Tower Research Fireside Chat on Wednesday, June... Read More...

71 views7 min read

Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund

CybinMay 31, 2023

- Share purchase agreement further strengthens Company’s position to deliver on value-driving clinical milestones -TORONTO, May 30, 2023--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ("Cybin"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psyched... Read More...

876 views2 min read

Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

Silo PharmaMay 30, 2023

Silo Pharma, Inc.Phase 2 of study will further investigate the peptides’ method, optimization, and binding affinity in human tissueENGLEWOOD CLIFFS, NJ, May 30, 2023 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, to... Read More...

383 views8 min read

Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreement and Provides Update on Its Board of Directors

Mydecine Innovations GroupMay 29, 2023

VANCOUVER, British Columbia, May 29, 2023 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to a... Read More...

423 views4 min read

Red Light Holland Reminder to Shareholders as the Company Celebrates its Third Listing Anniversary on The CSE by Conducting a Live Q&A Today at 1pm ET

Red Light HollandMay 26, 2023

Toronto, Ontario--(Newsfile Corp. - May 26, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the le... Read More...

1297 views6 min read

Numinus Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy

Numinus WellnessMay 25, 2023

First Numinus Network™ partner enters into agreement Recent cost containment initiatives have resulted in approximately $4.2 million of annualized savings, extending cash runway Well positioned to provide psychedelic-assisted therapy insurance reimbursement, as a result of recent US insurance payor code approval MDMA-assisted therapy e... Read More...

694 views8 min read

Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial

CybinMay 24, 2023

- CYB004, a deuterated dimethyltryptamine ("dDMT") molecule, has potential to overcome existing limitations of DMT and is protected by a composition of matter patent through 2041 –-- Parts A and B of Phase 1 study complete; Part C to determine safety, pharmacokinetic ("PK") and pharmacodynamic ("PD") of escalating doses of CYB004 in healt... Read More...

Calendar496 views6 min read

Red Light Holland Celebrates its Third Listing Anniversary on the CSE by Conducting a Live Q&A on May 26, 2023 at 1pm ET Hosted by CEO Todd Shapiro

Red Light HollandMay 19, 2023

Toronto, Ontario--(Newsfile Corp. - May 19, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the le... Read More...

1392 views6 min read

Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia™

Lobe SciencesMay 17, 2023

Distribution Agreement Grants Pentec Exclusive Distribution Rights for Altemia Lobe’s Novel Sickle Cell Anemia Medical FoodVANCOUVER, British Columbia, May 17, 2023--(BUSINESS WIRE)--Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a biopharmaceutical company focused on developing transformative medicines to treat orphan diseases t... Read More...

1367 views4 min read

Optimi Health Completes Harvest Of Psilocybe Cubensis For Delivery To The Australian Medical Market

Optimi HealthMay 17, 2023

<!-- Name:DistributionId Value:8841433 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value: --> <!-- Name:CustomerId Value:1214936 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:8d2713f1-7251-40f0-a501-e7bc86ec100c --> VANCOUVER, British... Read More...

1106 views4 min read

Optimi Health Granted Natural Health Product Site Licence By Health Canada

Optimi HealthMay 10, 2023

<!-- Name:DistributionId Value:8835803 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value: --> <!-- Name:CustomerId Value:1214936 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:78509552-a016-44dd-9a01-762dab27a0de --> VANCOUVER, British... Read More...

538 views8 min read

Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial

CybinMay 9, 2023

- Advancing to first-in-human dosing of CYB004, a proprietary deuterated DMT molecule -- CYB004 being developed to provide less invasive and more convenient dosing methods as compared with IV infused DMT -- Phase 1 topline data expected in Q3 2023 -TORONTO, May 09, 2023--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin"... Read More...

1385 views2 min read

Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease

Silo PharmaMay 9, 2023

<!-- Name:DistributionId Value:8834701 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:3763 --> <!-- Name:CustomerId Value:500069339 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:a9b7e2ab-bdd4-4b40-bbb8-91ab572edbcc --> ENGLEWOOD CL... Read More...

1310 views4 min read

Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical Research and Development

Optimi HealthMay 4, 2023

Optimi Health Corp.The Company’s entire cultivation facility has been mobilized to service supply agreementsVANCOUVER, British Columbia, May 04, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), today announced that it has entered into a CAD$1.2 million definitive supply agreement with a privat... Read More...

CalendarFinancials1482 views3 min read

COMPASS Pathways plc to announce first quarter 2023 financial results on 11 May 2023

COMPASS Pathways plcMay 4, 2023

COMPASS PathwaysLONDON, May 03, 2023 -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter 2023, and provide an update on recent business developments on 11 May... Read More...

860 views4 min read

Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19

Revive TherapeuticsMay 2, 2023

<!-- Name:DistributionId Value:8829672 --> <!-- Name:EnableQuoteCarouselOnPnr Value:True --> <!-- Name:IcbCode Value:4573 --> <!-- Name:CustomerId Value:1105448 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:7bb166ba-7a1b-4f4b-9e81-06921a47977b --> TORONTO, May 02... Read More...

27 views7 min read

Red Light Holland Publishes Report on Psilocybin Microdosing In Collaboration With NUBU Pharmaceuticals Aimed At NUBU’s Pharmaceutical’s Network Of Medical Doctors In Australasia

Red Light HollandApril 26, 2023

Toronto, Ontario--(Newsfile Corp. - April 26, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to t... Read More...

Financials48 views7 min read

Red Light Holland Engages World Famous Media Personality Mia Khalifa as Advisor to help with Social Media Guidance and Exposure and to Develop a Female-Focused Mushroom Brand

Red Light HollandApril 25, 2023

Toronto, Ontario--(Newsfile Corp. - April 25, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocy... Read More...

1333 views6 min read

Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues

Mydecine Innovations GroupApril 24, 2023

<!-- Name:DistributionId Value:8824006 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 --> <!-- Name:CustomerId Value:1212978 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:c8b054d4-caa2-4806-bba7-ed36e92d81ca --> VANCOUVER, Bri... Read More...

808 views3 min read

Silo Pharma to Present at Psychedelic Drug Development Conference

Silo PharmaApril 24, 2023

<!-- Name:DistributionId Value:8823351 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:3763 --> <!-- Name:CustomerId Value:500069339 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:34e57916-bdab-41da-870d-df833b99cbee --> ENGLEWOOD CL... Read More...

110 views6 min read

Lobe Sciences, Ltd. Provides Update on Vitamind

Lobe SciencesApril 22, 2023

Vancouver, British Columbia--(Newsfile Corp. - April 21, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today provides an update on its acquisition of the Vitamind Bran... Read More...

34 views8 min read

Red Light Holland Receives Certificate of Analysis for Their Dehydrated Homogenized Natural Psilocybin Developed and Tested by Partner CCrest Laboratories Aimed for Distribution with NUBU Pharmaceuticals in Australasia

Red Light HollandApril 22, 2023

Certificate of Analysis issued for processed psilocybin truffles imported from Red Light Holland's farm in the Netherlands by CCrest Laboratories.Child proof packaging has been sourced.Toronto, Ontario--(Newsfile Corp. - April 21, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland"), a company engage... Read More...

109 views4 min read

BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

BetterLife PharmaApril 20, 2023

<!-- Name:DistributionId Value:8810797 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 --> <!-- Name:CustomerId Value:1216524 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:50fed9d1-2a23-4863-a988-1b8c6fb6a146 --> VANCOUVER, Bri... Read More...

110 views4 min read

Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202

Bright Minds BiosciencesApril 20, 2023

Bright Minds Biosciences-- BMB-202 is a highly selective 5-HT2A agonist that exhibits a more than 30-fold selectivity over 5-HT2C and more than 500-fold selectivity over 5-HT2B ---- BMB-202 is the first clinical candidate from an extensive portfolio of selective 5-HT2A and 5-HT2A/2C agonists inspired from natural compound scaffolds --VANC... Read More...

Calendar365 views3 min read

Numinus to Participate in a Water Tower Research Fireside Chat on Wednesday, April 19, 2023

Numinus WellnessApril 17, 2023

VANCOUVER, BC, April 17, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will participate in a Water Tower Research Fireside Chat on Wednesday, Ap... Read More...

37 views4 min read

Numinus Launches New Website to Enhance its Client Experience

Numinus WellnessApril 14, 2023

VANCOUVER, BC, April 14, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has launched a new client website at www.numinus.com as part of its branding strategy to align all welln... Read More...

Financials36 views20 min read

Numinus Wellness Inc. Reports Q2 2023 Results

Numinus WellnessApril 13, 2023

Q2 2023 revenues grew 581.1% year-over-year to $5.4 million Q2 2023 gross margin increased to 39.3% from 29.1% in Q2 2022 Gross profit of $2.1 million, increased 820.9% year-over-year Strong cash position of $19.7 million New licensing model designed to drive accelerated clinic growth with lower capital expenditures All financial ... Read More...

37 views8 min read

Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy

CybinApril 12, 2023

TORONTO, April 12, 2023--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced the launch of EMBARK Open Access ("EMBARK OA"), a f... Read More...

Calendar83 views4 min read

Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

Bright Minds BiosciencesApril 10, 2023

<!-- Name:DistributionId Value:8804303 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 --> <!-- Name:CustomerId Value:1215554 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:5a4f8d74-a5c7-45ff-825b-146eb8df4874 --> — Presentation... Read More...

372 views10 min read

Red Light Holland Announces AEM New Brunswick Shiitake Mushrooms Are Available in over 100 Locations Including All 47 Farm Boy Stores in Ontario, Canada

Red Light HollandApril 4, 2023

AEM New Brunswick Shiitake Mushrooms, via distribution partners, are available in 47 Farm Boy stores across OntarioWith the addition of the Farm Boy locations, AEM New Brunswick produced Shiitake Mushrooms are now available in over 100 retail stores in Eastern Canada, including Loblaws owned retailers in Ottawa; Costco locations in both O... Read More...

LOIM & A35 views6 min read

Delic Holdings Corp. Signs LOI with Peter/PetraMD to Acquire Ketamine Wellness Centers and Facilitate Online Ketamine Treatments Nationwide

Delic HoldingsApril 4, 2023

VANCOUVER, British Columbia, April 03, 2023--(BUSINESS WIRE)--Peter/PetraMD, the largest online provider of hormone therapy for men and women in the United States, today announced the intent to acquire Ketamine Wellness Centers. If successful, the acquisition would represent an incredible on-ramp into the ketamine space for Peter/PetraMD.... Read More...

Capital Raise1533 views4 min read

Psyence Group Announces Closing of Fourth Tranche of Private Placement and Conversion of Convertible Debt Note

Psyence GroupApril 3, 2023

<!-- Name:DistributionId Value:8801048 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 --> <!-- Name:CustomerId Value:500076928 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:ba2994f2-82e6-432e-93fa-a87c6dcbd354 --> TORONTO, Apr... Read More...

550 views4 min read

Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech

Revive TherapeuticsApril 3, 2023

<!-- Name:DistributionId Value:8800324 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 --> <!-- Name:CustomerId Value:1105448 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:0daa5390-6b78-4d03-a2f9-2ba60342dce5 --> Purchased MDMA... Read More...

1436 views6 min read

Mydecine Innovations Group Provides Corporate Update

Mydecine Innovations GroupApril 3, 2023

<!-- Name:DistributionId Value:8800385 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 --> <!-- Name:CustomerId Value:1212978 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:65645da1-7c98-4b54-881c-2e94f2315969 --> VANCOUVER, Bri... Read More...

Financials884 views16 min read

Mydecine Reports Financial Results for the Year Ended December 2022

Mydecine Innovations GroupApril 1, 2023

<!-- Name:DistributionId Value:8800044 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 --> <!-- Name:CustomerId Value:1212978 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:2f34e3ac-d9d6-4437-b1b5-92cb789bdb78 --> DENVER, March ... Read More...

CalendarFinancials34 views3 min read

Numinus to Host Q2 2023 Results Conference Call on April 13, 2023

Numinus WellnessMarch 30, 2023

VANCOUVER, BC, March 30, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended February 28, 2023, after market close on Thursday, April 13, 2023. Inte... Read More...

117 views5 min read

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

Revive TherapeuticsMarch 28, 2023

Revive Therapeutics Ltd.First subject enrolled and initial top-line results expected in Q3-2023TORONTO, March 28, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disor... Read More...

123 views4 min read

Numinus Launches the Practitioner Certification Pathway

Numinus WellnessMarch 27, 2023

VANCOUVER, BC, March 27, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has launched the Numinus Certification Pathway – a collection of psychedelic-assisted therapy ("PAT") tr... Read More...

129 views8 min read

Red Light Holland and Mera Life Sciences Terminate Agreement in St. Vincent and the Grenadines

Red Light HollandMarch 23, 2023

Toronto, Ontario--(Newsfile Corp. - March 23, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the l... Read More...